Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...

Still, broad uptake has long been an uphill battle for the gene therapy as it competes with a variety of treatments including, Roche’s blockbuster Hemlibra, Sanofi’s newer sales driver Altuviiio and ...

New specialty pharmacy and infusion suite combines compassionate nursing and infusion expertise for patients managing ...

The biotech is developing a drug aimed at a protein called PACAP, which has emerged as a potentially new way to prevent the ...

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisApproval in adults and children aged 6 years and older supported by phase 3 study ...

Strong reactions have been sparked by the death of a 46-year-old man in Skyros, who had initially been diagnosed with ...

Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases ...

Sanofi and Regeneron's Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study ...

| DelveInsight The dynamics of the acromegaly market are anticipated to change due to extensive R&D, the entry of novel therapies such as Debio 4126 (Debiopharm International SA), ALXN2420 ...

Q4 2025 Earnings Call February 24, 2026 5:00 PM ESTCompany ParticipantsTryn Stimart - Chief Legal Officer, CCO, ...

Chinese partner Tonghua Dongbao completed BioChaperone® Lispro Phase 3 program with positive data on people with type 1 diabetes, completing the positive results obtained on type 2 diabetesContinued ...